Turkish questionnaire for scleroderma patients
Part of Skin clinical trials.
This study is adapting a questionnaire to measure how scleroderma affects your daily life. Your responses will help make the tool more useful for Turkish-speaking patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with scleroderma.
- You are 18 years old or older.
- You do not have advanced heart, lung, liver, or kidney disease, a neurological condition, or cancer.
- You are willing to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how scleroderma affects physical performance and daily function in children and adults. It aims to understand the impact of the disease on movement and everyday activities.
This study looks at how scleroderma affects chewing and swallowing in children and adults. It aims to help understand these problems better so care can be improved.
This trial looks at how systemic sclerosis affects daily function and mental well-being, including social and emotional factors. It may help patients understand their condition better.
This study is testing a new scale to measure what it's like to live with hand problems caused by systemic sclerosis (scleroderma). By answering questions about your daily hand function, you can help doctors better understand your experience and improve care.
This study compares skin samples from people with scleroderma and healthy volunteers to understand what goes wrong in the skin. It may help researchers find new treatment targets.
This study looks at how systemic sclerosis (a condition causing skin thickening and organ issues) starts and gets worse. It may help researchers find better ways to treat or manage it.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.